Vanda Pharmaceuticals Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $216.1M | $198.8M | $192.6M | $254.4M | $268.7M |
| Operating income | -$151.2M | -$40.7M | -$14.0M | $6.3M | $42.2M |
| Cash from operations | -$109.4M | -$15.8M | $12.8M | $32.0M | $64.2M |
| Capital expenditure | $998,000 | $490,000 | $383,000 | $679,000 | $552,000 |
| Free cash flow | -$110.4M | -$16.2M | $12.4M | $31.3M | $63.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $488.9M | $656.2M | $648.4M | $634.2M | $593.8M |
| Total liabilities | $161.8M | $117.7M | $103.5M | $107.0M | $88.9M |
Shares outstanding 60.1M · Free float 78.7%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.